Literature DB >> 24175193

Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Prophylaxis and treatment controversies.

Daniel Kl Cheuk1.   

Abstract

Hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome, is a major complication of hematopoietic stem cell transplantation and it carries a high mortality. Prophylaxis for hepatic VOD is commonly given to transplant recipients from the start of conditioning through the early weeks of transplant. However, high quality evidence from randomized controlled trials is scarce with small sample sizes and the trials yielded conflicting results. Although various treatment options for hepatic VOD are available, most have not undergone stringent evaluation with randomized controlled trial and therefore it remains uncertain which treatment offers real benefit. It remains controversial whether VOD prophylaxis should be given, which prophylactic therapy should be given, who should receive prophylaxis, and what treatment should be offered once VOD is established.

Entities:  

Keywords:  Hematopoietic stem cell transplantation; Hepatic veno-occlusive disease; Prophylaxis; Randomized controlled trial; Treatment

Year:  2012        PMID: 24175193      PMCID: PMC3782230          DOI: 10.5500/wjt.v2.i2.27

Source DB:  PubMed          Journal:  World J Transplant        ISSN: 2220-3230


  96 in total

1.  Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients.

Authors:  Ulrike Reiss; Morton Cowan; Alex McMillan; Biljana Horn
Journal:  J Pediatr Hematol Oncol       Date:  2002-12       Impact factor: 1.289

2.  Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study.

Authors:  R Chopra; J D Eaton; A Grassi; M Potter; B Shaw; C Salat; P Neumeister; G Finazzi; M Iacobelli; K Bowyer; H G Prentice; T Barbui
Journal:  Br J Haematol       Date:  2000-12       Impact factor: 6.998

3.  Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin.

Authors:  M Simon; T Hahn; L A Ford; B Anderson; D Swinnich; M R Baer; B Bambach; S H Bernstein; Z P Bernstein; M S Czuczman; J L Slack; M Wetzler; G Herzig; J Schriber; P L McCarthy
Journal:  Bone Marrow Transplant       Date:  2001-03       Impact factor: 5.483

4.  Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation.

Authors:  J Schriber; B Milk; D Shaw; N Christiansen; M Baer; J Slack; H Tezcan; M Wetzler; G Herzig
Journal:  Bone Marrow Transplant       Date:  1999-12       Impact factor: 5.483

5.  N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation.

Authors:  O Ringdén; M Remberger; S Lehmann; P Hentschke; J Mattsson; S Klaesson; J Aschan
Journal:  Bone Marrow Transplant       Date:  2000-05       Impact factor: 5.483

6.  Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation.

Authors:  J D Morris; R E Harris; R Hashmi; J E Sambrano; R A Gruppo; A T Becker; C L Morris
Journal:  Bone Marrow Transplant       Date:  1997-11       Impact factor: 5.483

7.  Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy.

Authors:  Ursula Haussmann; Joachim Fischer; Stefan Eber; Franziska Scherer; Reinhard Seger; Tayfun Gungor
Journal:  Haematologica       Date:  2006-06       Impact factor: 9.941

8.  The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation.

Authors:  K Ohashi; J Tanabe; R Watanabe; T Tanaka; H Sakamaki; A Maruta; S Okamoto; N Aotsuka; K Saito; M Nishimura; H Oh; M Matsuzaki; S Takahashi; S Yonekura
Journal:  Am J Hematol       Date:  2000-05       Impact factor: 10.047

9.  A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation.

Authors:  S H Park; M H Lee; H Lee; H S Kim; K Kim; W S Kim; C W Jung; Y H Im; S S Yoon; W K Kang; K Park; C H Park; S W Kim
Journal:  Bone Marrow Transplant       Date:  2002-01       Impact factor: 5.483

10.  Successful treatment of an infant with veno-occlusive disease developed after allogeneic bone marrow transplantation by tissue plasminogen activator, heparin and prostaglandin E1.

Authors:  M Higashigawa; M Watanabe; H Nishihara; N Tabata; E Azuma; M Ido; M Ito; M Sakurai
Journal:  Leuk Res       Date:  1995-07       Impact factor: 3.156

View more
  4 in total

1.  Veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic stem cell transplantation: Middle East/North Africa regional consensus on prevention, diagnosis and management.

Authors:  A H Al Jefri; H Abujazar; A Al-Ahmari; A Al Rawas; Z Al Zahrani; A Alhejazi; M A Bekadja; A Ibrahim; M Lahoucine; S Ousia; A Bazarbachi
Journal:  Bone Marrow Transplant       Date:  2016-11-28       Impact factor: 5.483

Review 2.  Acute kidney injury in pediatric hematopoietic cell transplantation: critical appraisal and consensus.

Authors:  Rupesh Raina; Rolla Abu-Arja; Sidharth Sethi; Richa Dua; Ronith Chakraborty; James T Dibb; Rajit K Basu; John Bissler; Melvin Bonilla Felix; Patrick Brophy; Timothy Bunchman; Khalid Alhasan; Dieter Haffner; Yap Hui Kim; Christopher Licht; Mignon McCulloch; Shina Menon; Ali Mirza Onder; Prajit Khooblall; Amrit Khooblall; Veronika Polishchuk; Hemalatha Rangarajan; Azmeri Sultana; Clifford Kashtan
Journal:  Pediatr Nephrol       Date:  2022-02-28       Impact factor: 3.651

3.  Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplant.

Authors:  Maria Sola; Valkal Bhatt; Meighan Palazzo; Kathleen E Cavalier; Sean M Devlin; Molly Maloy; Juliet N Barker; Hugo Castro-Malaspina; David Chung; Parastoo B Dahi; Ann A Jakubowski; Heather Landau; Esperanza B Papadopoulos; Miguel-Angel Perales; Craig Sauter; Roni Tamari; Nancy A Kernan; Sergio Giralt; James W Young; Jenna D Goldberg; Doris M Ponce
Journal:  Bone Marrow Transplant       Date:  2022-04-27       Impact factor: 5.174

Review 4.  Role of Pharmacogenetics in Hematopoietic Stem Cell Transplantation Outcome in Children.

Authors:  Raffaella Franca; Gabriele Stocco; Diego Favretto; Nagua Giurici; Giuliana Decorti; Marco Rabusin
Journal:  Int J Mol Sci       Date:  2015-08-10       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.